Physician profile
Amy Michelle Roth
NPI 1912293309
$2,854.17
in general payments reported to CMS, 2019-2025
30 companies · $691 in 2025
The $691 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $125 · 2021: $79.25 · 2022: $597 · 2023: $535 · 2024: $580 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $382.38 | 2019-2025 | |
| Amgen INC. | $377.66 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $356.36 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.71 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $219.61 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $193.83 | 2022-2025 | Leqvio |
| Teva Pharmaceuticals USA, INC. | $171.08 | 2022-2024 | Austedo Xr, Austedo |
| Lilly USA, LLC | $93.73 | 2023-2025 | Mounjaro, Kisunla, Zepbound |
| Radius Health, INC. | $82.90 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $70.76 | 2023-2025 | Horizant, Horizant, Edarbi |
| Dexcom, INC. | $66.77 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $66.36 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $61.96 | 2023-2025 | |
| Exact Sciences Corporation | $45.71 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $40.56 | 2022-2023 | Qulipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $37.81 | 2022-2024 | Trelegy Ellipta |
| Ardelyx, INC. | $32.11 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $31.59 | 2021-2024 | Airsupra |
| Ge Healthcare | $26.06 | 2024 | |
| Nabriva Therapeutics, Plc | $24.38 | 2022 | |
| Corium, LLC | $22.88 | 2022 | |
| Shield Therapeutics INC | $22.83 | 2024 | |
| Hikma Pharmaceuticals USA | $22.82 | 2020 | |
| Optinose US, INC. | $22.14 | 2022 | |
| Eisai INC. | $20.53 | 2024 | |
| Sanofi Pasteur INC. | $19.61 | 2019 | |
| Genentech USA, INC. | $17.96 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.25 | 2022 | |
| Alfasigma USA, INC. | $13.92 | 2020 | |
| Allergan, INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.